NOV 01 7007 E FORMATION DISCLOSURE

1

Sheet

STATEMENT BY APPLICANT

of

10

APPLICATION NO.: 10/719,493 ATTY. DOCKET NO.: C1039.70021US01
FILING DATE: November 23, 2003 CONFIRMATION NO.: 3218

APPLICANT: Krieg et al.

GROUP ART UNIT: 1643 EXAMINER: P. Tungaturthi

U.S. PATENT DOCUMENTS

Examiner's	Cite	U.S. Patent Doc	cument	Name of Patentee or Applicant of Cited	Date of Publication or Issue
Initials #	No.	Number	Kind Code	Document	of Cited Document MM-DD-YYYY
PKT		5,087,617		Smith	02-11-1992
		5,877,309		McKay et al.	03-02-1999
		5,955,059		Gilchrest et al.	09-21-1999
		5,997,858		Tovey et al.	12-07-1999
. ,		6,030,955		Stein et al.	02-29-2000
	Ì	6,221,882	Bl	Macfarlane	04-24-2001
		6,399,630	B1	Macfarlane	06-04-2002
		6,479,504	Bl	Macfarlane et al.	11-12-2002
		6,521,637	B2	Macfarlane	02-18-2003
		6,727,230	Bl	Hutcherson et al.	04-27-2004
		6,821,957	Bl	Krieg et al.	11-23-2004
		6,943,240	B2	Bauer et al.	09-13-2005
		6,949,520	Bl	Hartmann et al.	09-27-2005
		7,001,890	Bl	Wagner et al.	02-21-2006
		7,223,741	B2	Krieg	05-29-2007
		2001-0044416	A1	McCluskie et al.	11-22-2001
		2002-0091097	Al	Bratzler et al.	07-11-2002
		2002-0142977	A1	Raz et al.	10-03-2002
		2002-0156033	Al	Bratzler et al.	10-24-2002
		2002-0164341	A1	Davis et al.	11-07-2002
		2002-0165178	A1	Schetter et al	11-07-2002
	<u> </u>	2002-0198165	Al	Bratzler et al.	12-26-2002
	ļ	2003-0026782	Al	Krieg	02-02-2003
		2003-0026801	Al	Weiner et al.	02-06-2003
	<u> </u>	2003-0050263	A1	Krieg et al.	03-13-2003
	1	2003-0050268	A1	Krieg et al.	03-13-2003
	<u> </u>	2003-0055014	A1	Bratzler	03-20-2003
	<u> </u>	2003-0091599	A1	Davis et al.	05-15-2003
	ļ <u>.</u>	2003-0100527	A1	Krieg et al.	05-29-2003
		2003-0139364	A1	Krieg et al.	07-24-2003
		2003-0148316	Al	Lipford et al.	08-07-2003
	ļ	2003-0148976	Al	Krieg et al.	08-07-2003
	1	2003-0166001	A1	Lipford	09-04-2003

EXAMINER: DATE CONSIDERED: 18108

[#] EXAMINER: Initial if reference considered, whether or notitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Sheet 2 of 10

APPLICATION NO.: 10/719,493 ATTY. DOCKET NO.: C1039.70021US01

FILING DATE: November 23, 2003 CONFIRMATION NO.: 3218

APPLICANT: Krieg et al.

GROUP ART UNIT: 1643 EXAMINER: P. Tungaturthi

PKT	2003-0181406	Al	Schetter et al.	09-25-2003
	2003-0191079	Al	Krieg et al.	10-09-2003
	2003-0212026	Al	Krieg et al.	11-13-2003
	2003-0224010	Al	Davis et al.	12-04-2003
	2003-0232074	A1	Lipford et al.	12-18-2003
	2003-0232856	Al	Macfarlane	12-18-2003
	2004-0009949	Al	Krieg	01-15-2004
	2004-0030118	Al	Wagner et al.	02-12-2004
	2004-0053880	Al	Krieg	03-18-2004
	2004-0067902	A9	Bratzler et al.	04-08-2004
	2004-0067905	Al	Krieg	04-08-2004
	2004-0087534	Al	Krieg et al.	05-06-2004
	2004-0087538	Al	Krieg et al.	05-06-2004
	2004-0092472	Al	Krieg	05-13-2004
1.	2004-0106568	Al	Krieg et al.	06-03-2004
	2004-0131628	Al	Bratzler et al.	07-08-2004
	2004-0132685	Al	Krieg et al.	07-08-2004
	2004-0142469	Al	Krieg et al.	07-22-2004
	2004-0143112	Al	Krieg et al.	07-22-2004
-	2004-0147468	Al	Krieg et al.	07-29-2004
	2004-0152649	A1	Krieg	08-05-2004
	2004-0152656	Al	Krieg et al.	08-05-2004
	2004-0152657	Al	Krieg et al.	08-05-2004
	2004-0162258	· Al	Krieg et al.	08-19-2004
	2004-0162262	Al	Krieg et al.	08-19-2004
	2004-0167089	A1	Krieg et al.	08-26-2004
	2004-0171150	A1	Krieg et al.	09-02-2004
	2004-0171571	Al	Krieg et al.	09-02-2004
	2004-0181045	Al	Krieg et al.	09-16-2004
	2004-0198680	Al	Krieg	10-07-2004
	2004-0198688	Al	Krieg et al.	10-07-2004
	2004-0229835	Al	Krieg et al.	11-18-2004
	2004-0234512	Al	Wagner et al.	11-25-2004
	2004-0235770	Al	Davis et al.	11-25-2004
	2004-0235774	Al	Bratzler et al.	11-25-2004
	2004-0235777	Al	Wagner et al.	11-25-2004
	2004-0235778	Al	Wagner et al.	11-25-2004
1	2004-0266719	Al	McCluskie et al.	12-30-2004

EXAMINER: PAGE | DATE CONSIDERED: | 31 08

EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Sheet 3 of 10

APPLICATION NO.: 10/719,493 ATTY. DOCKET NO.: C1039.70021US01

FILING DATE: November 23, 2003 CONFIRMATION NO.: 3218

APPLICANT: Krieg et al.

GROUP ART UNIT: 1643 EXAMINER: P. Tungaturthi

PKT	2005-0004061	A1	Krieg et al.	01-06-2005
	2005-0004062	Al	Krieg et al.	01-06-2005
	2005-0009774	A1	Krieg et al.	01-13-2005
	2005-0032734	Al	Davis et al.	02-10-2005
	2005-0032736	A1	Krieg et al.	02-10-2005
	2005-0037403	A1	Krieg et al.	02-17-2005
	2005-0037985	A1	Krieg et al.	02-17-2005
	2005-0043529	A1	Davis et al.	02-24-2005
	2005-0049215	A1	Krieg et al.	03-03-2005
	2005-0049216	A1	Krieg et al.	03-03-2005
	2005-0054601	Al	Wagner et al.	03-10-2005
	2005-0054602	Al	Krieg et al.	03-10-2005
	2005-0059619	A1	Krieg et al.	03-17-2005
	2005-0059625	A1	Krieg et al.	03-17-2005
	2005-0070491	A1	Krieg et al.	03-31-2005
	2005-0075302	Al	Hutcherson et al.	04-07-2005
	2005-0100983	A1	Bauer et al.	05-12-2005
	2005-0101554	Al	Krieg et al.	05-12-2005
	2005-0101557	A1	Krieg et al.	05-12-2005
	2005-0119273	A1	Lipford et al.	06-02-2005
	2005-0123523	A1	Krieg et al.	06-09-2005
	2005-0130911	A1	Uhlmann et al.	06-16-2005
	2005-0148537	Al	Krieg et al.	07-07-2005
	2005-0169888	Al	Hartman et al.	08-04-2005
	2005-0171047	Al	Krieg et al.	08-04-2005
	2005-0181422	Al	Bauer et al.	08-18-2005
	2005-0182017	Al	Krieg	08-18-2005
	2005-0197314	A1_	Krieg et al.	09-08-2005
	2005-0214355	A1	Klinman et al.	09-29-2005
	2005-0215501	Al	Lipford et al.	09-29-2005
	2005-0233995	A1	Krieg et al.	10-20-2005
	2005-0233999	A1	Krieg et al.	10-20-2005
	2005-0239732	A1	Krieg et al.	10-27-2005
	2005-0239733	A1	Jurk et al.	10-27-2005
	2005-0239734	A1	Uhlmann et al.	10-27-2005
	2005-0239736	A1	Krieg et al.	10-27-2005
	2005-0244379	A1	Krieg et al.	11-03-2005
<u> </u>	2005-0244380	Al	Krieg et al.	11-03-2005

EXAMINER:

POM

DATE CONSIDERED:

1/31/08

[&]quot;EXAMINER: Initial if reference considered, whether or notitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT Sheet 4 of 10 APPLICATION NO.: 10/719,493 ATTY. DOCKET NO.: C1039.70021US01 FILING DATE: November 23, 2003 CONFIRMATION NO.: 3218 APPLICANT: Krieg et al. GROUP ART UNIT: 1643 EXAMINER: P. Tungaturthi

PKT	2005-0245477	Αl	Krieg et al.	11-03-2005
	2005-0250726	Al	Krieg et al.	11-10-2005
	2005-0256073	Al	Lipford et al.	11-17-2005
	2005-0267064	A1	Krieg et al.	12-01-2005
	2005-0277604	Al	Krieg et al.	12-15-2005
	2005-0277609	A1	Krieg et al.	12-15-2005
	2006-0003955	Al	Krieg et al.	01-05-2006
	2006-0003962	A1	Ahluwalia et al.	01-05-2006
	2006-0019916	A1	Krieg et al.	01-26-2006
	2006-0019923	A1	Davis et al.	01-26-2006
	2006-0058251	A1	Krieg et al.	03-16-2006
	2006-0089326	Al	Krieg et al.	04-27-2006
	2006-0094683	Al	Krieg et al.	05-04-2006
	2006-0140875	· A1	Krieg et al.	06-29-2006
	2006-0154890	A1	Bratzler et al.	07-13-2006
	2006-0172966	A1	Lipford et al.	08-03-2006
	2006-0188913	Al	Krieg et al.	08-24-2006
	2006-0211639	Al	Bratzler et al.	09-21-2006
	2006-0211644	Al	Krieg et al.	09-21-2006
	2006-0229271	Al	Krieg et al.	10-12-2006
	2006-0241076	A1	Uhlmann et al.	10-26-2006
	2006-0246035	Al	Ahluwalia et al.	11-02-2006
	2006-0286070	Al	Hartmann et al.	12-21-2006
	2006-0287263	Al	Davis et al.	12-21-2006
	2007-0009482	Al	Krieg et al.	01-11-2007
	2007-0010470	Al	Krieg et al.	01-11-2007
	2007-0037767	Al	Bratzler et al.	02-15-2007
	2007-0065467	A1	Krieg et al.	03-22-2007
	2007-0066553	Al	Krieg et al.	03-22-2007
	2007-0066554	A1	Krieg et al.	03-22-2007
	2007-0078104	A1	Krieg et al.	04-05-2007
	2007-0129320	A9	Davis et al.	06-07-2007
	2007-0142315	A1	Forsbach et al.	06-21-2007
	2007-0184465	A1	Wagner et al.	08-09-2007
	2007-0202128	A1	Krieg et al.	08-30-2007
	2007-0224210	A1 .	Krieg et al.	09-27-2007
l l	2007-0232622	A1	Lipford et al.	10-04-2007

EXAMINER:	DATE CONSIDERED:
-----------	------------------

^{*} EXAMINER: Initial if reference considered, whether or notitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTC			1 PTO/SR/08)	APPLICATION NO.: 10/719,493	ATTY. DOCKET NO.: C1039.70021US01
	M PTO-1449/A and B (modified PTO/SB/08) NFORMATION DISCLOSURE		•	FILING DATE: November 23, 2003	CONFIRMATION NO.: 3218
I -	EMENT BY		·	APPLICANT: Krieg et al.	
Sheet	5	of	10	GROUP ART UNIT: 1643	EXAMINER: P. Tungaturthi

FOREIGN PATENT DOCUMENTS

Examiner's	Cite	For	eign Patent Docu	ment	Name of Patentee or Applicant of Cited	Date of	Translation
Initials #	No.	Office/ Country	Number	Kind Code	Document	Publication of Cited Document MM-DD-YYYY	(Y/N)
PKT		wo	95/17507	A1	Biognostik Gesellschaft Für Biomolekulare Diagnostik MBH [DE]	06-29-1995	
						1	
		l					Į

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials #	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
		[No Author Listed] CpG 7909: PF 3512676, PF-3512676. Drugs R D. 2006;7(5):312-6.	
PKT		ANITESCU et al., Interleukin-10 functions in vitro and in vivo to inhibit bacterial DNA-induced secretion of interleukin-12. J Interferon Cytokine Res. 1997 Dec;17(12):781-8.	
		CHACE et al., Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. Clin Immunol Immunopathol. 1997 Aug;84(2):185-93.	
		COHEN, Selective anti-gene therapy for cancer: principles and prospects. Tohoku J Exp Med. 1992 Oct;168(2):351-9.	
		FRIEDBERG et al., Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity. Blood. 2005 Jan 15;105(2):489-95. Epub 2004 Sep 9.	
		HIGAKI et al., Mechanisms involved in the inhibition of growth of a human B lymphoma cell line, B104, by anti-MHC class II antibodies. Immunol Cell Biol. 1994 Jun;72(3):205-14.	
		HINKULA et al., Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes. J Virol. 1997 Jul;71(7):5528-39.	
		KRIEG et al., Lymphocyte activation mediated by oligodeoxynucleotides or DNA containing novel un-methylated CpG motifs. American College of Rheumatology 58 th National Scientific Meeting. Minneapolis, Minnesota, October 22, 1994. Abstracts. Arthritis Rheum. 1994 Sep;37(9 Suppl).	
		KRIEG et al., Bacterial DNA or oligonucleotides containing CpG motifs protect mice from lethal L. monocytogenes challenge. 1996 Meeting on Molecular Approaches to the Control of Infectious Diseases. Cold Spring Harbor Laboratory, September 9-13, 1996:116.	
	<u></u>	KRIEG et al., Infection. In: McGraw Hill Book. 1996:242-3. KRIEG et al., Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. Trends Microbiol. 1996 Feb;4(2):73-6.	
		KRIEG, Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006 Jun;5(6):471-84.	
		KURAMOTO et al., Induction of T-cell-mediated immunity against MethA fibrosarcoma by intratumoral injections of a bacillus Calmette-Guerin nucleic acid fraction. Cancer Immunol Immunother. 1992;34(5):283-8.	
		LEIBSON et al., Role of gamma-interferon in antibody-producing responses. Nature. 1984 Jun 28-Jul 4;309(5971):799-801.	
		LIU et al., CpG ODN is an effective adjuvant in immunization with tumor antigen. J Invest Med. 1997 Sept7;45(7):333A.	

EXAMINER:	10 M	DATE CONSIDERED:
	\/	

^{*}EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO			1 PTO/SR/08)	APPLICATION NO.: 10/719,493	ATTY. DOCKET NO.: C1039.70021US01
	RM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE		•	FILING DATE: November 23, 2003	CONFIRMATION NO.: 3218
1	EMENT BY			APPLICANT: Krieg et al.	
Sheet	6	of	10	GROUP ART UNIT: 1643	EXAMINER: P. Tungaturthi

		
	LOKE et al., Delivery of c-myc antisense phosphorothioate oligodeoxynucleotides to hematopoietic	
PKT	cells in culture by liposome fusion: specific reduction in c-myc protein expression correlates with	1
	inhibition of cell growth and DNA synthesis. Curr Top Microbiol Immunol. 1988;141:282-9.	
	MACFARLANE et al., Unmethylated CpG-containing oligodeoxynucleotides inhibit apoptosis in	
	WEHI 231 B lymphocytes induced by several agents: evidence for blockade of apoptosis at a distal	}
	signalling step. Immunology. 1997 Aug;91(4):586-93.	<u> </u>
1 / }	MALTESE et al., Sequence context of antisense RelA/NF-kappa B phosphorothioates determines	
	specificity. Nucleic Acids Res. 1995 Apr 11;23(7):1146-51.	
	MUI et al., Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when	
	encapsulated and delivered in lipid particles. J Pharmacol Exp Ther. 2001 Sep;298(3):1185-92.	
	OCHIAI et al., Studies on lymphocyte subsets of regional lymph nodes after endoscopic injection of	
	biological response modifiers in gastric cancer patients. Int J Immunotherapy. 1986;11(4):259-65.	<u> </u>
	PERLAKY et al., Growth inhibition of human tumor cell lines by antisense oligonucleotides	ł
	designed to inhibit p120 expression. Anticancer Drug Des. 1993 Feb;8(1):3-14.	
	RATAJCZAK et al., In vivo treatment of human leukemia in a scid mouse model with c-myb	1
	antisense oligodeoxynucleotides. Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11823-7.	
	SONEHARA et al., Hexamer palindromic oligonucleotides with 5'-CG-3' motif(s) induce	
	production of interferon. J Interferon Cytokine Res. 1996 Oct;16(10):799-803.	
	SPARWASSER et al., Bacterial DNA causes septic shock. Nature. 1997 Mar 27;386(6623):336-7.	
	STEIN et al., Problems in interpretation of data derived from in vitro and in vivo use of antisense	
	oligodeoxynucleotides. Antisense Res Dev. 1994 Summer;4(2):67-9.	
i I I	STEIN et al., Non-antisense effects of oligodeoxynucleotides. Antisense Technology. 1997; ch11:	
	241-64.	
	TAKATSUKI et al., Interleukin 6 perfusion stimulates reconstitution of the immune and	
	hematopoietic systems after 5-fluorouracil treatment. Cancer Res. 1990 May 15;50(10):2885-90.	<u> </u>
	TOKUNAGA et al Jpn. J. Infect. Dis 52, 1-11, 1999.	1
	WEIGEL et al., CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or	
	tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res. 2003 Aug 1;9(8):3105-14.	
	WEINER et al., The immunobiology and clinical potential of immunostimulatory CpG	
	oligodeoxynucleotides. J Leukoc Biol. 2000 Oct;68(4):455-63.	1
	WEINER et al., Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective	
	as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci U S A. 1997 Sep	
	30;94(20):10833-7.	
}	WEINER et al., Immunostimulatory CpG oligodeoxynucleotide is effective as an adjuvant in	
	inducing production of anti-idiotype antibody and is synergistic with GMCSF. Blood. 1996 Nov	
	15;88(10):Suppl. 1 pt. 1. Abstract #348.	
	YAMAMOTO, Cytokine production inducing action of oligo DNA. Rinsho Meneki. 1997; 29(9):	Yes
	1178-84. Japanese.	163
	ZHAO et al., Pattern and kinetics of cytokine production following administration of	
	phosphorothioate oligonucleotides in mice. Antisense Nucleic Acid Drug Dev. 1997 Oct;7(5):495-	1
	502.	
	Patent Interference No. 105,171. Iowa Preliminary Motion 3 (for judgment based on failure to	
	comply with 35 U.S.C. 135(b)). (Electronically filed, unsigned). June 7, 2004.	
L 1	Patent Interference No. 105,171. Iowa Preliminary Motion 4 (for judgment of no interference in	

|--|

EXAMINER: Initial if reference considered, whether or notitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)
INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

Sheet 7 of 10

APPLICATION NO.: 10/719,493

ATTY. DOCKET NO.: C1039.70021US01

FILING DATE: November 23, 2003

CONFIRMATION NO.: 3218

APPLICANT: Krieg et al.

GROUP ART UNIT: 1643

EXAMINER: P. Tungaturthi

	fact). (Electronically filed, unsigned). June 7, 2004.	
701	Patent Interference No. 105,171. Iowa Preliminary Motion 5 (for judgment based on lack of	
PKT	enablement). (Electronically filed, unsigned). June 7, 2004.	
	Patent Interference No. 105,171. Iowa Preliminary Motion 6 (for judgment based on lack of	
1	adequate written description). (Electronically filed, unsigned). June 7, 2004.	
	Patent Interference No. 105,171. Iowa Preliminary Motion 7 (motion to redefine interference to	
	designate claims as not corresponding to the Count). (Electronically filed, unsigned). June 7, 2004.	
	Patent Interference No. 105,171. Iowa Preliminary Motion 8 (contingent motion to redefine the	
	Count). (Electronically filed, unsigned). June 7, 2004.	
	Patent Interference No. 105,171. Iowa Preliminary Motion 9 (motion for benefit of earlier	
	application). (Electronically filed, unsigned). June 7, 2004.	
	Patent Interference No. 105,171. Iowa Preliminary Motion 10 (contingent motion to redefine the	
	interference by adding a continuation application). (Electronically filed, unsigned). July 2, 2004.	
•	Patent Interference No. 105,171. Regents of the University of California Opposition 3 (to Iowa	
	Preliminary Motion 3 for judgment under 35 USC 135(b)). September 9, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Opposition 4 (to Iowa	
1 1	Preliminary Motion 4 for judgment of no interference in fact). September 9, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Opposition 5 (to Iowa	
1	Preliminary Motion 5 for judgment that UC's claim is not enabled). September 9, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Opposition 6 (to Iowa	
	Preliminary Motion 6 for judgment based on lack of adequate written description). September 9,	
	2004.	
	Patent Interference No. 105,171. Regents of the University of California Opposition 7 (to Iowa	
	Preliminary Motion 7 to redefine the interference). September 9, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Opposition 8 (to Iowa	
	Preliminary Motion 8 to redefine the Count). September 9, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Response 9 (to Iowa	
	Contingent Motion 9 for benefit). September 9, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Opposition 10 (to Iowa	
	Contingent Motion 10 to redefine the interference). September 9, 2004.	
1 1 1 1 1 1 1 1	Patent Interference No. 105,171. Regents of the University of California Opposition 11 (to Iowa	
	Contingent Motion 11 to suppress). October 15, 2004.	
	Patent Interference No. 105,171. Iowa Reply 3 (in support of Iowa Preliminary Motion 3 for	
	judgment under 35 U.S.C. §135(b)) (Electronically filed, unsigned). October 15, 2004.	
	Patent Interference No. 105,171. Iowa Reply 4 (in support of Iowa Preliminary Motion for judgment	
	of no interference in fact) (Electronically filed, unsigned). October 15, 2004.	
	Patent Interference No. 105,171. Iowa Reply 5 (in support of Iowa Preliminary Motion 5 for	
	judgment that UC's claim 205 is not enabled) (Electronically filed, unsigned). October 15, 2004.	
] [Patent Interference No. 105,171. Iowa Reply 6 (in support of Iowa Preliminary Motion 6 for	
	judgment based on lack of adequate written description) (Electronically filed, unsigned). October	
	15, 2004.	
	Patent Interference No. 105,171. Iowa Reply 7 (in support of Iowa Preliminary Motion 7 to redefine	
	the interference) (Electronically filed, unsigned). October 15, 2004.	
	Patent Interference No. 105,171. Iowa Reply 8 (in support of Iowa Preliminary Motion 8 to redefine	
	the count) (Electronically filed, unsigned). October 15, 2004.	

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or notitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/719,493	ATTY. DOCKET NO.: C1039.70021US01	
	•		•	FILING DATE: November 23, 2003	CONFIRMATION NO.: 3218	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICANT: Krieg et al.		
Sheet 8 of 10			10	GROUP ART UNIT: 1643	EXAMINER: P. Tungaturthi	

	Patent Interference No. 105,171. Iowa Reply 10 (in support of Iowa Preliminary Motion 10 to	
I PKT I	redefine the interference) (Electronically filed, unsigned). October 15, 2004.	
7	Patent Interference No. 105,171. Iowa Reply 11 (in support of Iowa Miscellaneous Motion to	
	suppress). (Electronically filed, unsigned). October 18, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Preliminary Statement.	
	June 7, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 1 (to	
	designate additional claims of Iowa patent as corresponding to the Count). June 7, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 2 (for	
	judgment based on lack of written description support and introducing new matter). June 7, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 3 (for	
	judgment based on anticipation). June 7, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 4 (for	
	judgment based on obviousness). June 7, 2004.	
 	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 5 (for	
	judgment based on anticipation). June 7, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Preliminary Motion 6 (for	
1	judgment based on inequitable conduct). June 7, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Contingent Preliminary	
	Motion 7 (for benefit of an earlier application under 37 CFR 1.633(j)). July 2, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Contingent Preliminary	
	Motion 8 (to add additional claims under 37 CFR 1.633(c)(2) and (i)). July 2, 2004.	
	Amended Claims for Application Number 09/265,191, filed March 10, 1999.	
	Patent Interference No. 105,171. Iowa Opposition 1 (opposition to motion to designate additional	:
1 1 1	claims as corresponding to the Count) (Electronically filed, unsigned). September 9, 2004.	
	Patent Interference No. 105,171. Iowa Opposition 2 (opposition to motion for judgment based on	·····
	lack of written description support and introducing new matter) (Electronically filed, unsigned).	
	September 9, 2004.	
	Patent Interference No. 105,171. lowa Opposition 3 (opposition to motion for judgment based on	
	anticipation) (Electronically filed, unsigned). September 9, 2004.	
	Patent Interference No. 105,171. Iowa Opposition 4 (opposition to motion for judgment based on	
	obviousness) (Electronically filed, unsigned). September 9, 2004.	
	Patent Interference No. 105,171. Iowa Opposition 5 (opposition to motion for judgment based on	
	anticipation) (Electronically filed, unsigned). September 9, 2004.	
	Patent Interference No. 105,171. Iowa Opposition 6 (opposition to motion for judgment based on	
	inequitable conduct) (Electronically filed, unsigned). September 9, 2004.	
	Patent Interference No. 105,171. Iowa Opposition 7 (opposition to motion for benefit of an earlier	
	application under 7 CFR 1.633(j)) (Electronically filed, unsigned). September 9, 2004.	
	Patent Interference No. 105,171. Iowa Opposition 8 (opposition to motion to add additional claims	
	under 37 CFR 1.633 (2) and (i)) (Electronically filed, unsigned). September 9, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Reply 1 (to lowa's	
	opposition to UC's motion to designate Iowa claims as corresponding to the Count). October 15,	
	2004.	
	Patent Interference No. 105,171. Regents of the University of California Reply 2 (to Iowa's	
	opposition to UC Preliminary Motion 2 for Judgment). October 15, 2004.	

EXAMINER:	DATE CONSIDERED:
-----------	------------------

[#] EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08)				APPLICATION NO.: 10/719,493	ATTY. DOCKET NO.: C1039.70021US01	
	•		•	FILING DATE: November 23, 2003	CONFIRMATION NO.: 3218	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT Sheet 9 of 10				APPLICANT: Krieg et al.		
			10	GROUP ART UNIT: 1643	EXAMINER: P. Tungaturthi	

-1.5	Patent Interference No. 105,171. Regents of the University of California Reply 3 (to Iowa's	
PKT	Opposition to UC Preliminary Motion 3 for Judgment). October 15, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Reply 4 (to Iowa's	
	Opposition to UC Preliminary Motion 4 for Judgment). October 15, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Reply 5 (to Iowa's	
	Opposition to UC Preliminary Motion 5 for Judgment). October 15, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Reply 6 (to Iowa's	•
 	opposition to UC Preliminary Motion 6 for judgment). October 15, 2004. Patent Interference No. 105,171. Regents of the University of California Reply 7 (to Iowa's	
	Opposition to UC Preliminary Motion 7 for Benefit). October 15, 2004.	
	Patent Interference No. 105,171. Regents of the University of California Reply 8 (to Iowa's	
	Opposition to UC Preliminary Motion 8 to add additional claims). October 15, 2004.	
	Patent Interference No. 105,171. Decision on Motion under 37 CFR §41.125. March 10, 2005.	
	Patent Interference No. 105,171. Judgment and Order. March 10, 2005.	
	Patent Interference No. 105,171. Regents of the University of California. Brief of Appellant. July 5, 2005.	
	Patent Interference No. 105,171. University of Iowa and Coley Pharmaceutical Group, Inc. Brief of Appellees. August 17, 2005.	
	Patent Interference No. 105,171. Regents of the University of California. Reply Brief of Appellant. September 6, 2005.	
	Patent Interference No. 105,171. Regents of the University of California. Decision of CAFC. July 17, 2006.	
	Patent Interference No. 105,526. Krieg Substantive Motion 1 (for unpatentability based on interference estoppel). (Electronically filed, unsigned).	
	Patent Interference No. 105,526 Krieg Substantive Motion 2 (for judgment based on inadequate written description and/or enablement). (Electronically filed, unsigned). June 18, 2007.	
	Patent Interference No. 105,526. Krieg Contingent Responsive Motion (to add new claims 104 and 105). (Electronically filed, unsigned). July 25, 2007.	
	Patent Interference No. 105,526. Krieg Substantive Motion 3 (for judgment based on prior art). (Electronically filed, unsigned). June 18, 2007.	
	Patent Interference No. 105,526. Raz Motion 1 (Unpatentability of Krieg Claims under 35 U.S.C. § 112, First Paragraph). (Electronically filed, unsigned). June 18, 2007.	
	Patent Interference No. 105,526. Raz Motion 2 (Raising a Threshold Issue of No Interference-in-Fact). (Electronically filed, unsigned). June 18, 2007.	
	Patent Interference No. 105,526 Raz Motion 3 (Krieg's Claims are Unpatentable Over Prior Art	_
	Under 35 U.S.C. § 102(b)) (Electronically filed, unsigned). June 18, 2007.	
	Patent Interference No. 105,526. Raz Motion 4 (To Designate Krieg Claims 46 and 82-84 as	
	Corresponding to Count 1). (Electronically filed, unsigned). June 18, 2007.	
	Patent Interference No. 105,526. Raz Responsive Miscellaneous Motion 5 (To revive the Raz	
	Parent Application) (Electronically filed, unsigned) July 25, 2007.	
	Patent Interference No. 105,526. Raz Contingent Responsive Motion 6 (To Add a New Claim 58)	
 	(Electronically filed, unsigned) July 25, 2007. Patent Interference No. 105,526. Krieg Opposition 1 (Opposition to Motion for Lack of Enablement	
	and Written Description) (Electronically filed, unsigned) September 10, 2007.	
	The state of the s	

EXAMINER:	B.0 W	DATE CONSIDERED:

[&]quot;EXAMINER: Initial if reference considered, whether or notcitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449/A and B (modified PTO/SB/08) INFORMATION DISCLOSURE STATEMENT BY APPLICANT				APPLICATION NO.: 10/719,493	ATTY. DOCKET NO.: C1039.70021US01
				FILING DATE: November 23, 2003 CONFIRMATION NO.: 3218	
				APPLICANT: Krieg et al.	
				CDOLID ADTILDUT 1642	THE PARTY OF THE P
Sheet 10 of 10		GROUP ART UNIT: 1643	EXAMINER: P. Tungaturthi		

PKJ	Patent Interference No. 105,526. Krieg Opposition 2 (to Raz Motion 2) (Electronically filed, unsigned) September 10, 2007.
	Patent Interference No. 105,526. Krieg Opposition 3 (To Raz Motion 3) (Electronically filed, unsiged) September 10, 2007.
	Patent Interference No. 105,526. Krieg Opposition 4 (Opposition to Motion for Designating Claims 46 and 82-84 as Corresponding to the Court) (Electronically filed, unsigned) September 10, 2007.
	Patent Interference No. 105,526. Krieg Opposition 6 (Opposition to Raz Contingent Responsive Motion 6) (Electronically filed, unsigned) September 10, 2007.
	Patent Interference No. 105,526. Raz Opposition 1 (Opposing Krieg Substantive Motion 1) (Electronically filed, unsigned) September 10, 2007.
	Patent Interference No. 105,526. Raz Opposition 2 (Opposing Krieg Substantive Motion 2) (Electronically filed, unsigned) September 10, 2007.
	Patent Interference No. 105,526. Raz Opposition 4 (Opposing Krieg Contingent Responsive Motion to Add New Claims 104 and 105) (Electronically filed, unsigned) September 10, 2007.
	Patent Interference No. 105,526. Krieg Reply 1 (Reply to Raz opposition 1) October 5, 2007
	Patent Interference No. 105,526. Krieg Reply 2 (Reply to Raz opposition 2) October 5, 2007
	Patent Interference No. 105,526. Krieg Reply 4 (Reply to Raz opposition 4) October 5, 2007
	Patent Interference No. 105,526. Raz Reply 1 (Reply to Krieg opposition 1) October 5, 2007
	Patent Interference No. 105,526. Raz Reply 2 (Reply to Krieg opposition 2) October 5, 2007
	Patent Interference No. 105,526. Raz Reply 3 (Reply to Krieg opposition 3) October 5, 2007
	Patent Interference No. 105,526. Raz Reply 4 (Reply to Krieg opposition 4) October 5, 2007
	Patent Interference No. 105,526. Raz Reply 6 (Reply to Krieg opposition 6) October 5, 2007
	PRESS RELEASE, January 2007, "Coley Pharmaceutical Group Updates Hepatitis C Drug Development Strategy".
	PRESS RELEASE, June 2007, "Coley Pharmaceutical Group Announces Pfizer's Discontinuation of Clinical Trials for PF-3512676 Combined with Cytotoxic Chemotherapy in Advanced Non Small Cell Lung Cancer".

^{*}a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. ___, filed ___, and relied upon for an earlier filing date under 35 U.S.C. 120 (continuation, continuation-in-part, and divisional applications).

[NOTE – No copies of U.S. patents, published U.S. patent applications, or pending, unpublished patent applications stored in the USPTO's Image File Wrapper (IFW) system, are included. See 37 CFR §1.98 and 1287OG163. Copies of all other patent(s), publication(s), unpublished, pending U.S. patent applications, or other information listed are provided as required by 37 CFR §1.98 unless 1) such copies were provided in an IDS in an earlier application that complies with 37 CFR §1.98, and 2) the earlier application is relied upon for an earlier filing date under 35 U.S.C. §120.]

EXAMINER:	DATE CONSIDERED:	
P. Cimp	80/12/10	

EXAMINER: Initial if reference considered, whether or notitation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.